462-43-1

Usage

Uses

Used in Pharmaceutical Industry:
3-Fluoropropan-1-ol is used as a reagent for the synthesis of fluorinated amino acids, such as DL-erythro-4-fluoroglutamine (F591630). These fluorinated amino acids have potential applications in the development of new drugs and therapeutic agents.
Used in Radiochemistry and Imaging:
3-Fluoropropan-1-ol is also used as a reagent for the synthesis of labeled N-desmethyl-loperamide analogues. These compounds have potential use as imaging radiotracers, which can be utilized in diagnostic imaging techniques to visualize and study biological processes in living organisms.

InChI:InChI=1/C3H7FO/c4-2-1-3-5/h5H,1-3H2

Upstream product

• 627-30-5 1-chloro-3-hydroxypropane 
• 504-63-2 trimethyleneglycol 
• 115952-64-2 ((3-fluoropropoxy)methyl)benzene 
• 71742-12-6 1-(3-Hydroxy-propyl)-2,4,6-triphenyl-pyridinium; fluoride 
• 614-50-6 benzoic acid-(3-fluoro-propyl ester) 

Downstream Products

• 312-68-5 3-fluoropropyl tosylate 
• 1093659-65-4 2β-carbo(3-fluoropropoxy)-3β-(3'-bromophenyl)tropane 
• 1221502-45-9 4-bromo-5-(4-fluorophenyl)-1-(3-fluoropropyl)-3-methyl-1H-pyrazole 
• 1227184-48-6 3-(3-fluoro-propoxy)-benzoic acid methyl ester 
• 1246093-55-9 4-(benzo[4,5]imidazo[1,2-a]pyrimidin-2-yl)-N-(3-fluoropropyl)aniline 
• 133368-73-7 C₁₆H₁₅F₂N₃O₃ 
• 1301167-85-0 2-[4-[1-(3-fluoropropyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]phenoxymethyl]-6-methylpyridine hydrochloric acid 
• 1325724-18-2 dibenzyl-[2-(3-fluoropropoxy)ethyl]amine 
• 71-23-8 propan-1-ol 
• 1220909-51-2 C₁₇H₁₉FN₄O 
• 1224433-08-2 (E)-3-(pyridin-2-ylethynyl)cyclohex-2-enone O-(3-fluoropropoxy)methyl oxime 
• 930283-29-7 ethyl 2-(2,4-dichlorophenyl)-1-(4-(3-fluoropropoxy)phenyl)-5-methyl-1H-imidazole-4-carboxylate 
• 895582-89-5 ethyl 1-(2,4-dichlorophenyl)-5-[4-(3-fluoropropoxy)phenyl]-4-methyl-1H-pyrazole-3-carboxylate 
• 178423-46-6 3-Chloro-2-(4-chloro-3-(1'-fluoroprop-3'-oxy)phenyl)-4,5,6,7-tetrahydroindazole 

Relevant academic research and scientific papers

Preparation method of 3-fluoro-1-propanol

The present invention discloses a method for preparing 3- fluoro-1-propanol, the method is as follows: under the protection of nitrogen or argon, spray-dried potassium fluoride, 3-chloro-1-propanol as raw material, diethylene glycol as a solvent, polyethylene glycol --400 (PEG--400) as a phase transfer catalyst (PTC), in the pressure-resistant upper head connected to the filler distillation column in the reaction kettle while stirring reaction while distillation, while collecting the boiling range at the top of the distillation column between 120 ° C - --140 ° C initial fractions The collected primary fraction is re-distilled once, and the fraction with a boiling range of 127.5 °C to 128.5 °C is collected, that is, the product 3-fluoro-1-propanol. The purity of the product is detected by gas chromatograph; the structure of the product is characterized by nuclear magnetic resonance hydrogen spectroscopy and nuclear magnetic resonance carbon spectroscopy. The present invention takes the method of distillation while reacting to prepare 3-fluoro-1-propanol, the required equipment is simple, the investment is small, the by-products in the reaction process are few and easy to remove, the solvent diethylene glycol can be recycled and recycled many times, and it is easy to achieve industrial production.

Effect of Partially Fluorinated N-Alkyl-Substituted Piperidine-2-carboxamides on Pharmacologically Relevant Properties

The modulation of pharmacologically relevant properties of N-alkyl-piperidine-2-carboxamides was studied by selective introduction of 1–3 fluorine atoms into the n-propyl and n-butyl side chains of the local anesthetics ropivacaine and levobupivacaine. The basicity modulation by nearby fluorine substituents is essentially additive and exhibits an exponential attenuation as a function of topological distance between fluorine and the basic center. The intrinsic lipophilicity of the neutral piperidine derivatives displays the characteristic response noted for partially fluorinated alkyl groups attached to neutral heteroaryl systems. However, basicity decrease by nearby fluorine substituents affects lipophilicities at neutral pH, so that all partially fluorinated derivatives are of similar or higher lipophilicity than their non-fluorinated parents. Aqueous solubilities were found to correlate inversely with lipophilicity with a significant contribution from crystal packing energies, as indicated by variations in melting point temperatures. All fluorinated derivatives were found to be somewhat more readily oxidized in human liver microsomes, the rates of degradation correlating with increasing lipophilicity. Because the piperidine-2-carboxamide core is chiral, pairs with enantiomeric N-alkyl groups are diastereomeric. While little response to such stereoisomerism was observed for basicity or lipophilicity, more pronounced variations were observed for melting point temperatures and oxidative degradation.

Towards the development of new subtype-specific muscarinic receptor radiopharmaceuticals - Radiosynthesis and ex vivo biodistribution of [ 18F]3-(4-(2-(2-(2-fluoroethoxy)ethoxy)ethylthio)-1,2, 5-thiadiazol-3-yl)-1-methyl-1,2,5,6-tetrahydropyrid

Muscarinic receptors have been implicated in neurological disorders including Alzheimer's disease, Parkinson's disease, and schizophrenia. Nineteen derivatives of thiadiazolyltetrahydropyridine (TZTP), a core that has previously shown high affinities towa

FLUORINATED DIHYDROTETRABENAZINE ETHER IMAGING AGENTS AND PROBES

The present invention provides novel fluorinated ether compounds having structure I wherein R1 is a C2-C10 fluorinated aliphatic radical; R2 is a C1-C10 aliphatic radical, or a C3/sub

INTERMEDIATES FOR FLUORINATED DIHYDROTETRABENAZINE ETHER IMAGING AGENTS AND PROBES

The present invention provides novel fluorophilic compounds having structure VI wherein R1 is a C2-C20 aliphatic, a C3-C20 cycloaliphatic, or a C3-C20 aromatic radical comprising at least one functional group susceptible to reaction with nucleophilic fluoride ion or an electrophilic fluorinating agent; R2 is a C1-C10 aliphatic radical, or a C3-C10 cycloaliphatic radical; R3 is hydrogen or a C1-C10 aliphatic radical; and R4 is hydrogen or a C1-C10 aliphatic radical. The fluorophilic compounds are provided in both racemic and enantiomerically enriched forms and are useful as intermediates in the preparation of novel PET imaging agents and probes useful in the discovery and performance assessment of PET imaging agents. The fluorophilic compounds are particularly useful in the preparation of PET imaging agents and probes having a high affinity for VMAT-2, a biomarker implicated in human diabetes and other illnesses such as Parkinson's disease.

Radiosynthesis of 3-(3-[18F]fluoropropoxy)-4-(benzyloxy)-N-[(1- dimethylaminocyclopentyl)methyl]-5-methoxybenzamide, a potential PET radiotracer for the glycine transporter GlyT-2

The recently described selective and potent GlyT2 antagonist, 4-benzyloxy-3, 5-dimethoxy-N-[(1-dimethylaminocyclopentyl) methyl]benzamide (IC50 = 16 nM) provided an important additional tool to further characterize GlyT2 pharmacology. In order to identify an effective PET radioligand for in vivo assessment of the GlyT-2 transporter, 3-(3-[ 18F]fluoropropoxy)-4-(benzyloxy)-N-((1-dimethylaminocyclopentyl) methyl)-5-methoxybenzamide ([18F]3), a novel analog of 4-benzyloxy-3,5-dimethoxy-N-[(1-dimethylaminocyclopentyl) methyl]benzamide was synthesized using a one-pot, two-step method. The NCA radiofluorination of 1,3-propanediol di-p-tosylate in the presence of K2CO3 and Kryptofix-222 in acetonitrile gave 81% 3-[18F]fluoropropyl tosylate, which was subsequently coupled with 4-benzyloxy-3-hydroxy-5-methoxy-N-[(1- dimethylaminocyclopentyl) methyl]-benzamide in the same reaction vessel. Solvent extraction and HPLC (Eclipse XDB-C8 column, 80/20/0.1 MeOH/H 2O/Et3N, 3.0 ml/min) gave [18F]3 in 98.5% radiochemical purity. The radiochemical yield was determined to be 14.0-16.2% at EOS, and the specific activity was 1462 ± 342 GBq/μmol. The time of synthesis and purification was 128 min. The final product was prepared as a sterile saline solution suitable for in vivo use. Copyright

Triazolopyrimidines

Novel triazolopyrimidines of the formula in which R1, R2, R3 and X have the meanings given in the description, a process for preparing these novel substances and their use for controlling undesirable microorganisms and animal pests. Novel amines of the formula in which R4 has the meanings given in the description, and processes for their preparation.

REACTION OF HYDROXY AND CARBONYL COMPOUNDS WITH SULFUR TETRAFLUORIDE IX. REACTIONS OF GLYCOLS WITH SULFUR TETRAFLUORIDE

Selective substitution of one of the hydroxyl groups by a fluorine atom occurs in the reactions of 1,2-, 1,3-, and 1,4-glycols with sulfur tetrafluoride under mild conditions.The regioselectivity of substitution in the case of unsymmetrical glycols depends on the electronic nature of the groups present in the molecules of the initial compounds.

The Preparation of Primary Alkyl and Benzyl Fluorides from the Corresponding Primary Amines

N-substituted 2,4,6-triphenylpyridinium fluorides (in contrast to these and other tetrafluoroborates) thermolyse to the corresponding primary alkyl and benzyl fluorides.The pyridinium fluorides are made from 2,4,6-triphenylpyrylium fluoride and the relevant amine.